SITE001-0263

SITE001 (USA) › SITE001-0263

SITE001-0263

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2026-07-10

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-12 (study day 55); relationship: not assessed

mild assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-03 (study day 46); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.